Panbela Therapeutics Inc
NASDAQ:PBLA
Panbela Therapeutics Inc
NASDAQ:PBLA
Price:
0.381 USD
-6.85%
Market Closed
Updated:
May 8, 2024
Panbela Therapeutics Inc
Cash from Financing Activities
|
Panbela Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Panbela Therapeutics Inc
NASDAQ:PBLA
|
Cash from Financing Activities
$26.1m
|
CAGR 3-Years
36%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Panbela Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
26.1m
USD
26.1m
USD
Based on the financial report for Dec 31, 2023, Panbela Therapeutics Inc's Cash from Financing Activities amounts to 26.1m USD.
What is Panbela Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
48%
48%
Over the last year, the Cash from Financing Activities growth was 389%. The average annual Cash from Financing Activities growth rates for Panbela Therapeutics Inc have been 36% over the past three years , 48% over the past five years .
You don't have any saved screeners yet
